Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 7807

1.

Label-free quantitative proteomics of mouse cerebrospinal fluid detects BACE1 protease substrates in vivo.

Dislich B, Wohlrab F, Bachhuber T, Mueller S, Kuhn PH, Hogl S, Meyer-Luehmann M, Lichtenthaler SF.

Mol Cell Proteomics. 2015 Jul 2. pii: mcp.M114.041533. [Epub ahead of print]

PMID:
26139848
2.

Multiplexed Fluorescent Immunodetection Using Low Autofluorescence Immobilon(®)-FL Membrane.

Park J, Mabuchi M, Sharma A.

Methods Mol Biol. 2015;1314:195-205. doi: 10.1007/978-1-4939-2718-0_22.

PMID:
26139269
3.

Biomarkers for Alzheimer's disease: a controversial topic.

Frisoni GB, Visser PJ.

Lancet Neurol. 2015 Jun 29. pii: S1474-4422(15)00150-7. doi: 10.1016/S1474-4422(15)00150-7. [Epub ahead of print] No abstract available.

PMID:
26139024
4.
5.

Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease.

Forlenza OV, Diniz BS, Teixeira AL, Radanovic M, Talib LL, Rocha NP, Gattaz WF.

Neuromolecular Med. 2015 Jul 3. [Epub ahead of print]

PMID:
26138246
6.

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls.

Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, Kornhuber J, Hansson O, Minthon L, Spitzer P, Maler JM, Zetterberg H, Blennow K, Lewczuk P.

Alzheimers Res Ther. 2015 Jul 1;7(1):40. doi: 10.1186/s13195-015-0124-3. eCollection 2015.

PMID:
26136856
7.

Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis.

Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin JJ, De Deyn PP, Engelborghs S.

Front Neurol. 2015 Jun 17;6:138. doi: 10.3389/fneur.2015.00138. eCollection 2015.

PMID:
26136723
Free Article
8.

Integrative biomarker discovery in neurodegenerative diseases.

Carreiro AV, Mendonça A, de Carvalho M, Madeira SC.

Wiley Interdiscip Rev Syst Biol Med. 2015 Jul 2. doi: 10.1002/wsbm.1310. [Epub ahead of print]

PMID:
26136395
9.

Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, Wimo A, Winblad B, Schott JM, Blennow K, Eriksdotter M, Zetterberg H.

Brain. 2015 Jun 30. pii: awv181. [Epub ahead of print]

PMID:
26133663
10.

In-vivo brain neuroimaging provides a gateway for integrating biological and clinical biomarkers of Alzheimer's disease.

Cui J, Zufferey V, Kherif F.

Curr Opin Neurol. 2015 Aug;28(4):351-7. doi: 10.1097/WCO.0000000000000225.

PMID:
26132531
11.

Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.

Candeias EM, Sebastião IC, Cardoso SM, Correia SC, Carvalho CI, Plácido AI, Santos MS, Oliveira CR, Moreira PI, Duarte AI.

World J Diabetes. 2015 Jun 25;6(6):807-27. doi: 10.4239/wjd.v6.i6.807. Review.

12.

Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study.

Quiroz YT, Schultz AP, Chen K, Protas HD, Brickhouse M, Fleisher AS, Langbaum JB, Thiyyagura P, Fagan AM, Shah AR, Muniz M, Arboleda-Velasquez JF, Munoz C, Garcia G, Acosta-Baena N, Giraldo M, Tirado V, Ramírez DL, Tariot PN, Dickerson BC, Sperling RA, Lopera F, Reiman EM.

JAMA Neurol. 2015 Jun 29. doi: 10.1001/jamaneurol.2015.1099. [Epub ahead of print]

PMID:
26121081
13.

A Novel Application of Multiscale Entropy in Electroencephalography to Predict the Efficacy of Acetylcholinesterase Inhibitor in Alzheimer's Disease.

Tsai PH, Chang SC, Liu FC, Tsao J, Wang YH, Lo MT.

Comput Math Methods Med. 2015;2015:953868. doi: 10.1155/2015/953868. Epub 2015 May 18.

14.

Clinical and research value of the new diagnostic criteria for Alzheimer's disease.

Wei C.

Shanghai Arch Psychiatry. 2015 Apr 25;27(2):124-5. doi: 10.11919/j.issn.1002-0829.215046.

15.

Are the revised diagnostic criteria for Alzheimer's disease useful in low- and middle-income countries?

Cece Y, Shifu X.

Shanghai Arch Psychiatry. 2015 Apr 25;27(2):119-23. doi: 10.11919/j.issn.1002-0829.215001.

16.

Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes.

Hohman TJ, Samuels LR, Liu D, Gifford KA, Mukherjee S, Benson EM, Abel T, Ruberg FL, Jefferson AL; Alzheimer's Neuroimaging Initiative.

Neurobiol Aging. 2015 Jun 6. pii: S0197-4580(15)00305-X. doi: 10.1016/j.neurobiolaging.2015.05.021. [Epub ahead of print]

PMID:
26119224
17.

Improved Diagnostic Multimodal Biomarkers for Alzheimer's Disease and Mild Cognitive Impairment.

Martínez-Torteya A, Treviño V, Tamez-Peña JG.

Biomed Res Int. 2015;2015:961314. doi: 10.1155/2015/961314. Epub 2015 May 28.

18.

The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia.

Gordon BA, Najmi S, Hsu P, Roe CM, Morris JC, Benzinger TL.

Neuroimage Clin. 2015 Apr 30;8:246-52. doi: 10.1016/j.nicl.2015.04.017. eCollection 2015.

19.

Longitudinal cognitive decline in the AIBL cohort: the role of APOE ε4 status.

Albrecht MA, Szoeke C, Maruff P, Savage G, Lautenschlager NT, Ellis KA, Taddei K, Martins R, Masters CL, Ames D, Foster JK; AIBL Research Group.

Neuropsychologia. 2015 Jun 20. pii: S0028-3932(15)30057-9. doi: 10.1016/j.neuropsychologia.2015.06.008. [Epub ahead of print]

PMID:
26102189
20.

Will PET Amyloid Imaging Lead to Overdiagnosis of Alzheimer Dementia?

Dubroff JG, Nasrallah IM.

Acad Radiol. 2015 Jun 18. pii: S1076-6332(15)00061-6. doi: 10.1016/j.acra.2015.02.005. [Epub ahead of print] Review.

PMID:
26100192
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk